Bio-Techne Holds FY2026 Outlook Despite Cell-Therapy Timing Headwind

Transcript intelligence

What changed

The current analysis highlights a 1% organic revenue decline and a 90-basis-point adjusted operating-margin expansion to 29.9%. It adds a quantified 200-400-basis-point Q2 cell-therapy timing headwind, while management maintained the low-single-digit FY2026 growth outlook and highlighted upcoming Ella and ProximityScope launches.

Guidance delta

Management maintained its low-single-digit FY2026 growth outlook; the supplied analysis does not indicate a revision.

Key takeaways

• Organic revenue declined 1% year over year, while adjusted operating margin expanded 90 basis points to 29.9%.
• Management attributed a 200-400 basis-point Q2 headwind to cell-therapy timing; without it, the underlying business would have grown about 1% organically.
• Large-pharma demand, ProteinSimple instruments, spatial biology, and China activity were identified as offsets.
• Upcoming launches include an ultrasensitive Ella cartridge and the ProximityScope spatial-biology assay.
• The balance sheet was described as strong, with $145 million of cash, low leverage, and $5.4 million of capex.

Management priorities

• Release the ultrasensitive Ella cartridge for Simple Plex.
• Commercialize the ProximityScope spatial-biology assay.
• Scale the COMET multi-omic instrument platform.
• Complete the Wilson Wolf acquisition by the end of 2027.
• Continue sustainability initiatives targeting further emissions reductions.